보고서 요약(국문)

시장 개요
활성 의약품 원료(API) 시장 보고서는 시장 규모, 현재 동향, 경쟁 환경 및 미래 시장 전망에 대한 분석을 제공합니다. 제약 산업의 성장과 만성 질환 증가로 인해 API 수요가 증가하고 있습니다. 특히 아시아 태평양 지역은 인구 증가와 의료 인프라 개선으로 인해 수요가 급증하고 있습니다. 화이자(Pfizer, Inc.), 노바티스(Novartis International AG) 등 주요 기업들이 시장에서 활발하게 활동하면서 경쟁이 심화되고 있습니다.
활성 의약품 원료(API)는 약물의 효과를 나타내는 구성 요소입니다. 복합 요법과 같은 일부 약물은 여러 활성 성분을 포함하여 다양한 증상을 치료하거나 다양한 방식으로 작용합니다. API는 연구 개발 및 상업 생산 단계 모두에서 고도의 기술 산업 공정을 사용하여 생산됩니다.
시장 동향 및 추세
전 세계 활성 의약품 원료 시장의 성장은 만성 질환 증가와 전 세계적으로 고령 인구 증가에 의해 주도되고 있습니다. 바이오의약품의 활용 증가와 의약품 제조를 위한 연구 개발 투자 확대는 모두 세계 활성 의약품 원료(API) 시장 성장에 기여하고 있습니다.
바이오시밀러 제품 사용 증가가 시장 성장을 견인할 것입니다.
바이오시밀러는 오리지널 생물학적 의약품과 동일한 엄격한 규제 기준을 충족하지 않는, 저작권이 있는 생물학적 의약품의 제네릭 버전입니다. 따라서 오리지널 생물학적 의약품의 특허 및 기타 지적 재산권이 만료될 가능성이 높으며, 이는 바이오시밀러의 시장 진입을 가능하게 합니다. 결과적으로 바이오시밀러 제품 사용 증가는 예측 기간 동안 활성 의약품 원료(API) 시장 성장을 촉진할 것입니다.
또한 신약 및 생물학적 제품 출시, 인수, 협력, 지역 확장 등은 시장 안정화를 위한 전략적 이니셔티브이며, 이는 단기적으로 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 2020년 Quartic.ai와 Bright Path Labs는 중요한 활성 의약품 원료(API)의 연속 생산을 위한 AI 기반 기술 개발을 위해 협력했습니다. 활성 의약품 원료(API) 시장은 전통적으로 항감염제, 당뇨병 치료제, 심혈관 질환 치료제, 진통제 및 통증 관리 약물과 같은 의약품이 주도해 왔습니다. 그러나 연구 개발 동향에 따르면, 틈새 치료 영역을 겨냥한 새로운 제형에 사용되는 복합 API 개발에 대한 수요가 증가하고 있습니다. 이는 중요한 소분자 의약품 생산에도 필요한 것일까요?
또 다른 중요한 성장 동력은 전 세계적으로 증가하는 고령 인구입니다. 유엔에 따르면 2019년 전 세계 65세 이상 인구는 7억 300만 명이었습니다. 이처럼 높은 고령 인구는 많은 만성 및 급성 질환 발병률을 높이고, 이러한 질환의 영향을 완화하기 위한 새로운 약물에 대한 수요를 증가시켜 시장 성장을 촉진합니다.
높은 제조 비용은 시장 성장을 저해할 수 있습니다.
API의 높은 제조 비용은 시장 참여자들이 직면한 주요 과제 중 하나입니다. 제조업체는 cGMP와 같은 기준을 준수하기 위해 제조 시설 개선에 막대한 투자를 해야 하는 경우가 많습니다. 여기에는 생산 시설 개조, 적격성 평가 요건 및 프로세스 숙지, 규제 당국의 요구 사항을 충족하는 제품 효능 및 안전성 시험 자료 구축 등이 포함됩니다. 또한, 소량 생산 기업의 경우 규제 승인 획득 비용이 상대적으로 더 높습니다. API의 화학적 합성은 종종 고가의 희귀한 빌딩 블록과 원자재를 필요로 하므로 API 제조 비용이 더욱 증가합니다. 이러한 요인들은 예측 기간 동안 시장 성장을 저해하는 요인으로 작용합니다.
COVID-19가 활성 의약품 원료(API) 시장 성장에 미치는 영향
COVID-19 팬데믹은 각국과 주요 기업들이 COVID-19 치료 수요를 충족하기 위해 대량의 원료를 생산함에 따라 시장에 긍정적인 영향을 미쳤습니다. COVID-19 발생으로 인해 제약 회사들은 더 많은 환자를 대상으로 하는 방향으로 사업 모델을 전환했습니다. 예를 들어, 미국은 코로나바이러스 치료제로 인도산 하이드록시클로로퀸(HCQ) 수입을 요청했습니다. 이 바이러스는 캐나다의 의약품 공급망에도 차질을 빚게 하여 캐나다 환자들에게 문제를 야기할 수 있습니다. 캐나다의 주요 제약 회사들은 새로운 시장 진출을 위해 중국 외 다른 국가들과의 협력 프로그램을 확대하고 있습니다. 2020년 3월 24일, WHO는 코로나19에 가장 유망한 4가지 약물에 대한 대규모 글로벌 임상 시험을 시작한다고 발표했습니다. 각국은 코로나19에 효과적으로 대응할 백신을 개발하고 대량 생산하기 위한 경쟁을 벌이고 있습니다. 팬데믹으로 인한 경제적, 사회적 부담으로 인해 각국 정부는 전 세계적으로 백신 개발 자금 지원을 확대하고 있습니다. 이러한 요인들이 팬데믹 기간 동안 시장 성장을 견인할 것입니다.

세분화
심혈관 질환 부문은 예측 기간(2023-2030년) 동안 가장 빠른 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다.
심혈관 질환의 높은 유병률로 인해 다양한 심혈관 질환 치료제를 사용하는 인구가 많아 심혈관 질환 부문이 시장에서 상당한 비중을 차지하고 있습니다. 유럽심장학회(European Society of Cardiology)의 2019년 통계에 따르면, 심혈관 질환(CVD)은 유럽에서 여전히 주요 사망 원인이자 주요 질병 유발 요인입니다. 현재 EU에서는 매년 600만 건 이상의 CVD 신규 환자가 발생하고 있으며, 유럽 전체에서는 1,100만 건 이상이 발생하고 있습니다. EU에서 CVD를 앓고 있는 사람이 거의 4,900만 명에 달하며, EU 경제에 미치는 비용은 연간 2,100억 유로에 이릅니다. 이러한 요인이 예측 기간 동안 해당 부문의 성장을 견인할 것입니다.
지역 분석
북미 지역은 전 세계 활성 의약품 원료(API) 시장에서 가장 큰 시장 점유율을 차지하고 있습니다.
북미는 현재 활성 의약품 원료 시장을 주도하고 있으며, 향후 몇 년 동안 이러한 강세를 유지할 것으로 예상됩니다. 질병 발생률 증가와 고령화 인구 증가로 인해 북미 지역의 시장 점유율은 앞으로 더욱 확대될 것으로 전망됩니다. 북미 지역에서는 미국이 시장의 대부분을 차지하고 있습니다.

최근 미국 정부가 수입 관세 및 세금을 인상하는 등 정치 및 무역 정책을 시행함에 따라 제조업체의 운영 비용이 증가하고 가격 경쟁 압력이 심화될 것으로 예상됩니다. 또한 FDA는 신약 승인 신청 수수료를 인상하고 미국 시장에 고품질 제품을 공급하기 위해 해외 위탁 생산 시설에 대한 정기 검사 횟수를 늘렸습니다. 이러한 요인들이 해당 지역 시장의 성장을 견인하고 있습니다.
기업 및 경쟁 환경
의약품 원료(API) 시장은 국내외 기업들이 활발하게 경쟁하는 매우 경쟁적인 시장입니다. 시장 성장에 기여하는 주요 기업으로는 Aurobindo Pharma, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Novartis AG, BASF SE, Boehringer Ingelheim GmbH, Dr. Reddy’s Laboratories Ltd, Lupin Ltd, Mylan NV, Sun Pharmaceutical Industries Ltd 등이 있습니다. 주요 기업들은 신제품 출시, 인수, 협력 등 다양한 성장 전략을 채택하고 있으며, 이는 전 세계 API 시장 성장에 기여하고 있습니다. 예를 들어, 2020년 4월 베링거인겔하임은 노던 바이오로직스를 인수했습니다. 이 인수를 통해 베링거인겔하임의 항암제 제품 포트폴리오가 확대되었습니다.
노바티스 AG
개요: 노바티스 AG는 스위스에 본사를 둔 제약 회사입니다. 이 회사는 브랜드 및 제네릭 전문의약품, 활성 의약품 원료(API), 바이오시밀러, 안과용 제품을 개발, 제조 및 판매합니다.
제품 포트폴리오:
항감염제: 산도즈 항감염제 및 API 사업부는 합리적인 가격의 고품질 의약품 중간체, 활성 의약품 원료(API) 및 완제 의약품을 통합적으로 제공합니다.

보고서 요약(영어 원문)

Market Overview
The Active Pharmaceutical Ingredients (API) market report provides an analysis of the market size, current trends, competitive landscape, and future market outlook. The demand for APIs is increasing due to the growth of the pharmaceutical industry and the rise in chronic diseases. The market is witnessing a surge in demand from the Asia-Pacific region, primarily due to the increasing population and improving healthcare infrastructure. The competitive rivalry is intensifying with major players such as Pfizer, Inc., Novartis International AG, and others actively operating in the market.
An active pharmaceutical ingredient (API) is a part of any drug that produces its effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. They are produced using highly technological industrial processes, both during the R&D and the commercial production phase.
Market Dynamics and Trends
The global active pharmaceutical ingredient market growth is driven by an increase in the number of chronic diseases and an increase in the number of geriatric populations around the world. The increased utilization of biopharmaceuticals and rising investments in research and development for drug manufacturing are all contributing to the growth of the global active pharmaceutical ingredients (API) market.
The surge in the use of biosimilar products will drive the market growth
Biosimilars are generic versions of copyrighted biologic medications that do not meet the same severe regulatory criteria as branded biologic medicines. Thus, the patents and other intellectual property rights for originator biologics are likely to expire, allowing biosimilars to join the market. As a result, the surge in the use of biosimilar products is propelling the growth of the active pharmaceutical ingredients (API) market during the forecast period.
Moreover, the launches of new drugs and biological products, acquisitions, collaborations, and regional expansions are some of the strategic initiatives to maintain stability in the market. This is likely to fuel market growth shortly. For instance, in 2020, Quartic.ai and Bright Path Labs collaborated to develop AI-based technology for the continuous manufacturing of critical AP The active pharmaceutical ingredients (API) market has traditionally been dominated by drugs, such as anti-infectives and diabetes, cardiovascular, analgesics, and pain management drugs. However, as per the R&D trends, the demand is shifting toward the development of complex APIs used in novel formulations, targeting niche therapeutic areas. Is that required for producing crucial small-molecule drugs?
Another important growth driver is the rise in the geriatric population around the world. According to the United Nations, there were 703 million people aged 65 and above worldwide in 2019. Such a high geriatric population gives way to contracting a lot of chronic and acute diseases which would require newer drugs to mitigate their effects, thus leading to a rise in market growth.
High manufacturing costs will hamper the market growth
The high manufacturing cost of APIs is one of the major challenges faced by market players. Manufacturers often have to make costly investments for improvements in their manufacturing facilities to ensure compliance with standards such as the cGMP. This includes the renovation of production facilities, inculcating familiarity with qualification requirements and processes, and building a dossier of product efficacy and safety tests that meet the requirements of regulatory authorities. Furthermore, the costs of obtaining regulatory approvals are relatively higher for firms with small volumes. The chemical synthesis of APIs also often requires expensive and uncommon building blocks and raw materials, which further adds to API manufacturing costs. These factors are hampering the growth of the market in the forecast period.
COVID-19 Impact on Active Pharmaceutical Ingredients Market Growth
The COVID-19 pandemic had a favorable impact on the market as the countries and major players are manufacturing huge amounts of ingredients to maintain the demand for the treatment of COVID-19. The outbreak of COVID-19 has led drug manufacturers to redirect their models to focus on a larger pool of patients. For instance, the United States requested that hydroxychloroquine (HCQ) be imported from India as a treatment for coronavirus. The virus has also disrupted the drug supply chain in Canada and may cause problems for patients in the country. Canadian pharma majors expand their programs with countries other than China to gain access to new regions. On March 24, 2020, the WHO announced that it had initiated a global mega-trial of the four most promising drugs against COVID-19. Countries are in a global race to develop and mass-produce an efficient vaccine to fight COVID-19. The economic and social burden of pandemics has prompted government bodies to increase funding for vaccine development on a global scale. These factors will drive the growth of the market during a pandemic.
Segmentation
The cardiovascular segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)
The cardiovascular segment holds a significant share due to the vast population using various CVD drugs owing to the high prevalence of cardiovascular diseases. According to the European Society of Cardiology 2019 Statistics, cardiovascular diseases (CVD) remain the leading cause of mortality and a major cause of morbidity in Europe. Currently, there are more than 6 million new cases of CVD in the EU and more than 11 million in Europe as a whole, every year. With almost 49 million people living with the disease in the EU, the cost to the EU economies is high at EUR 210 billion a year. This factor will drive the growth of the segment in the forecast period.
Geographical Analysis
North America region holds the largest market share of the global active pharmaceutical ingredient market
North America currently dominates the market for active pharmaceutical ingredients and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the increasing incidences of disease and the rising aging population. The United States holds the majority of the market in the North American region.
The recent political and trade policies implemented by the US government to increase import duties and taxes are expected to drive operational costs and increase the pricing pressure on the manufacturers. The FDA has also increased the application fees for new drug approvals and has increased the number of periodic inspections conducted on various off-shore contract manufacturing facilities to ensure the supply of high-quality products to the US market. These factors are driving the growth of the market in the region.
Companies and Competitive Landscape
The active pharmaceutical ingredient market is highly competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Aurobindo Pharma, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Novartis AG, BASF SE, Boehringer Ingelheim GmbH, Dr. Reddy’s Laboratories Ltd, Lupin Ltd, Mylan NV, Sun Pharmaceutical Industries Ltd among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the active pharmaceutical ingredient market globally. For instance, in April 2020, Boehringer Ingelheim acquired Northern Biologics. This acquisition broadened Boehringer Ingelheim’s oncology product portfolio.
Novartis AG
Overview: Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars, and ophthalmic products.
Product Portfolio:
Anti-Infectives: The Sandoz Anti-Infectives & API business is a fully-integrated provider of affordable, high-quality pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms.

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
3.1. Market Snippet By Type
3.2. Market snippet By Application
3.3. Market snippet By Nature
3.4. Market Snippet By Manufacturing type
3.5. Market Snippet by Region
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Infectious, Genetic, Cardiovascular, and Other Chronic Disorders
4.1.1.2. Increasing Adoption of Biologicals and Biosimilars
4.1.2. Restraints:
4.1.2.1. Drug Price Control Policies Across Various Countries
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before the COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or a Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
7.1.2. Market Attractiveness Index, By Type Segment
7.2. Synthetic API*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
7.3. Biotech API
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Cardiovascular*
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
8.3. Diabetes
8.4. Oncology
8.5. Orthopaedics
8.6. Neurology
8.7. NSAIDS
8.8. Others
9. By Nature
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Nature
9.1.2. Market Attractiveness Index, By Nature Segment
9.2. Generic API*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
9.3. Innovator API
10. By Manufacturing type
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Manufacturing type
10.1.2. Market Attractiveness Index, By Manufacturing Type Segment
10.2. Captive*
10.2.1. Introduction
10.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
10.3. Merchant
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Nature
11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Manufacturing type
11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. The U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Nature
11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Manufacturing type
11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. The U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Nature
11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Manufacturing type
11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Nature
11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Manufacturing type
11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Nature
11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Manufacturing type
12. Competitive Landscape
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
13. Company Profiles
13.1. Aurobindo Pharma*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Teva Pharmaceutical Industries Ltd
13.3. Pfizer Inc.
13.4. Novartis AG
13.5. BASF SE
13.6. Boehringer Ingelheim GmbH
13.7. Dr. Reddy’s Laboratories Ltd
13.8. Lupin Ltd
13.9. Mylan NV
13.10. Sun Pharmaceutical Industries Ltd(*LIST NOT EXHAUSTIVE)
14. DataM Intelligence
14.1. Appendix
14.2. About Us and Services
14.3. Contact Us

언급된 주요 기업들

Aurobindo Pharma, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Novartis AG, BASF SE, Boehringer Ingelheim GmbH, Dr. Reddy’s Laboratories Ltd, Lupin Ltd, Mylan NV

표 목록 (Tables)

List of Tables Table 1 Global Active Pharmaceutical Ingredients Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)

Table 2 Global Active Pharmaceutical Ingredients Market Value, By Type of Synthesis, 2025, 2029 & 2033 (US$ Billion)

Table 3 Global Active Pharmaceutical Ingredients Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)

Table 4 Global Active Pharmaceutical Ingredients Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)

Table 5 Global Active Pharmaceutical Ingredients Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 6 Global Active Pharmaceutical Ingredients Market Value, By Type, 2025, 2029 & 2033 (US$ Billion)

Table 7 Global Active Pharmaceutical Ingredients Market Value, By Type, 2022-2033 (US$ Billion)

Table 8 Global Active Pharmaceutical Ingredients Market Value, By Type of Synthesis, 2025, 2029 & 2033 (US$ Billion)

Table 9 Global Active Pharmaceutical Ingredients Market Value, By Type of Synthesis, 2022-2033 (US$ Billion)

Table 10 Global Active Pharmaceutical Ingredients Market Value, By Application, 2025, 2029 & 2033 (US$ Billion)

Table 11 Global Active Pharmaceutical Ingredients Market Value, By Application, 2022-2033 (US$ Billion)

Table 12 Global Active Pharmaceutical Ingredients Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)

Table 13 Global Active Pharmaceutical Ingredients Market Value, By End-User, 2022-2033 (US$ Billion)

Table 14 Global Active Pharmaceutical Ingredients Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 15 Global Active Pharmaceutical Ingredients Market Value, By Region, 2022-2033 (US$ Billion)

Table 16 North America Active Pharmaceutical Ingredients Market Value, By Type, 2022-2033 (US$ Billion)

Table 17 North America Active Pharmaceutical Ingredients Market Value, By Type of Synthesis, 2022-2033 (US$ Billion)

Table 18 North America Active Pharmaceutical Ingredients Market Value, By Application, 2022-2033 (US$ Billion)

Table 19 North America Active Pharmaceutical Ingredients Market Value, By End-User, 2022-2033 (US$ Billion)

Table 20 North America Active Pharmaceutical Ingredients Market Value, By Country, 2022-2033 (US$ Billion)

Table 21 Europe Active Pharmaceutical Ingredients Market Value, By Type, 2022-2033 (US$ Billion)

Table 22 Europe Active Pharmaceutical Ingredients Market Value, By Type of Synthesis, 2022-2033 (US$ Billion)

Table 23 Europe Active Pharmaceutical Ingredients Market Value, By Application, 2022-2033 (US$ Billion)

Table 24 Europe Active Pharmaceutical Ingredients Market Value, By End-User, 2022-2033 (US$ Billion)

Table 25 Europe Active Pharmaceutical Ingredients Market Value, By Country, 2022-2033 (US$ Billion)

Table 26 Asia-Pacific Active Pharmaceutical Ingredients Market Value, By Type, 2022-2033 (US$ Billion)

Table 27 Asia-Pacific Active Pharmaceutical Ingredients Market Value, By Type of Synthesis, 2022-2033 (US$ Billion)

Table 28 Asia-Pacific Active Pharmaceutical Ingredients Market Value, By Application, 2022-2033 (US$ Billion)

Table 29 Asia-Pacific Active Pharmaceutical Ingredients Market Value, By End-User, 2022-2033 (US$ Billion)

Table 30 Asia-Pacific Active Pharmaceutical Ingredients Market Value, By Country, 2022-2033 (US$ Billion)

Table 31 South America Active Pharmaceutical Ingredients Market Value, By Type, 2022-2033 (US$ Billion)

Table 32 South America Active Pharmaceutical Ingredients Market Value, By Type of Synthesis, 2022-2033 (US$ Billion)

Table 33 South America Active Pharmaceutical Ingredients Market Value, By Application, 2022-2033 (US$ Billion)

Table 34 South America Active Pharmaceutical Ingredients Market Value, By End-User, 2022-2033 (US$ Billion)

Table 35 South America Active Pharmaceutical Ingredients Market Value, By Country, 2022-2033 (US$ Billion)

Table 36 Middle East and Africa Active Pharmaceutical Ingredients Market Value, By Type, 2022-2033 (US$ Billion)

Table 37 Middle East and Africa Active Pharmaceutical Ingredients Market Value, By Type of Synthesis, 2022-2033 (US$ Billion)

Table 38 Middle East and Africa Active Pharmaceutical Ingredients Market Value, By Application, 2022-2033 (US$ Billion)

Table 39 Middle East and Africa Active Pharmaceutical Ingredients Market Value, By End-User, 2022-2033 (US$ Billion)

Table 40 Middle East and Africa Active Pharmaceutical Ingredients Market Value, By Country, 2022-2033 (US$ Billion)

Table 41 Pfizer Inc.: Overview

Table 42 Pfizer Inc.: Product Portfolio

Table 43 Pfizer Inc.: Key Developments

Table 44 Teva Pharmaceuticals USA, Inc.: Overview

Table 45 Teva Pharmaceuticals USA, Inc.: Product Portfolio

Table 46 Teva Pharmaceuticals USA, Inc.: Key Developments

Table 47 Merck KGaA: Overview

Table 48 Merck KGaA: Product Portfolio

Table 49 Merck KGaA: Key Developments

Table 50 AbbVie Inc.: Overview

Table 51 AbbVie Inc.: Product Portfolio

Table 52 AbbVie Inc.: Key Developments

Table 53 Aurobindo Pharma Limited: Overview

Table 54 Aurobindo Pharma Limited: Product Portfolio

Table 55 Aurobindo Pharma Limited: Key Developments

Table 56 Dr. Reddy’s Laboratories Ltd.: Overview

Table 57 Dr. Reddy’s Laboratories Ltd.: Product Portfolio

Table 58 Dr. Reddy’s Laboratories Ltd.: Key Developments

Table 59 Lupin: Overview

Table 60 Lupin: Product Portfolio

Table 61 Lupin: Key Developments

Table 62 Sun Pharmaceutical Industries Ltd.: Overview

Table 63 Sun Pharmaceutical Industries Ltd.: Product Portfolio

Table 64 Sun Pharmaceutical Industries Ltd.: Key Developments

Table 65 Divi's Laboratories Limited: Overview

Table 66 Divi's Laboratories Limited: Product Portfolio

Table 67 Divi's Laboratories Limited: Key Developments

Table 68 Cipla: Overview

Table 69 Cipla: Product Portfolio

Table 70 Cipla: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Active Pharmaceutical Ingredients Market Value, 2022-2033 (US$ Billion)

Figure 2 Global Active Pharmaceutical Ingredients Market Share, By Type, 2024 & 2033 (%)

Figure 3 Global Active Pharmaceutical Ingredients Market Share, By Type of Synthesis, 2024 & 2033 (%)

Figure 4 Global Active Pharmaceutical Ingredients Market Share, By Application, 2024 & 2033 (%)

Figure 5 Global Active Pharmaceutical Ingredients Market Share, By End-User, 2024 & 2033 (%)

Figure 6 Global Active Pharmaceutical Ingredients Market Share, By Region, 2024 & 2033 (%)

Figure 7 Global Active Pharmaceutical Ingredients Market Y-o-Y Growth, By Type, 2023-2033 (%)

Figure 8 Innovative (Branded) APIs Active Pharmaceutical Ingredients Market Value, 2022-2033 (US$ Billion)

Figure 9 Generic APIs Active Pharmaceutical Ingredients Market Value, 2022-2033 (US$ Billion)

Figure 10 Global Active Pharmaceutical Ingredients Market Y-o-Y Growth, By Type of Synthesis, 2023-2033 (%)

Figure 11 Synthetic APIs Type of Synthesis in Global Active Pharmaceutical Ingredients Market Value, 2022-2033 (US$ Billion)

Figure 12 Biotech/Biological APIs Type of Synthesis in Global Active Pharmaceutical Ingredients Market Value, 2022-2033 (US$ Billion)

Figure 13 Global Active Pharmaceutical Ingredients Market Y-o-Y Growth, By Application, 2023-2033 (%)

Figure 14 Oncology Application in Global Active Pharmaceutical Ingredients Market Value, 2022-2033 (US$ Billion)

Figure 15 Cardiovascular Diseases Application in Global Active Pharmaceutical Ingredients Market Value, 2022-2033 (US$ Billion)

Figure 16 Neurology & Psychiatry Disorders Application in Global Active Pharmaceutical Ingredients Market Value, 2022-2033 (US$ Billion)

Figure 17 Endocrinology / Metabolic Disorders Application in Global Active Pharmaceutical Ingredients Market Value, 2022-2033 (US$ Billion)

Figure 18 Respiratory Diseases Application in Global Active Pharmaceutical Ingredients Market Value, 2022-2033 (US$ Billion)

Figure 19 Gastrointestinal Diseases Application in Global Active Pharmaceutical Ingredients Market Value, 2022-2033 (US$ Billion)

Figure 20 Musculoskeletal Disorders Application in Global Active Pharmaceutical Ingredients Market Value, 2022-2033 (US$ Billion)

Figure 21 Others Application in Global Active Pharmaceutical Ingredients Market Value, 2022-2033 (US$ Billion)

Figure 22 Global Active Pharmaceutical Ingredients Market Y-o-Y Growth, By End-User, 2023-2033 (%)

Figure 23 Pharmaceutical & Biotech Companies End-User in Global Active Pharmaceutical Ingredients Market Value, 2022-2033 (US$ Billion)

Figure 24 CDMOs/CMOs End-User in Global Active Pharmaceutical Ingredients Market Value, 2022-2033 (US$ Billion)

Figure 25 Others End-User in Global Active Pharmaceutical Ingredients Market Value, 2022-2033 (US$ Billion)

Figure 26 Global Active Pharmaceutical Ingredients Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 27 North America Active Pharmaceutical Ingredients Market Value, 2022-2033 (US$ Billion)

Figure 28 North America Active Pharmaceutical Ingredients Market Share, By Type, 2024 & 2033 (%)

Figure 29 North America Active Pharmaceutical Ingredients Market Share, By Type of Synthesis, 2024 & 2033 (%)

Figure 30 North America Active Pharmaceutical Ingredients Market Share, By Application, 2024 & 2033 (%)

Figure 31 North America Active Pharmaceutical Ingredients Market Share, By End-User, 2024 & 2033 (%)

Figure 32 North America Active Pharmaceutical Ingredients Market Share, By Country, 2024 & 2033 (%)

Figure 33 Europe Active Pharmaceutical Ingredients Market Value, 2022-2033 (US$ Billion)

Figure 34 Europe Active Pharmaceutical Ingredients Market Share, By Type, 2024 & 2033 (%)

Figure 35 Europe Active Pharmaceutical Ingredients Market Share, By Type of Synthesis, 2024 & 2033 (%)

Figure 36 Europe Active Pharmaceutical Ingredients Market Share, By Application, 2024 & 2033 (%)

Figure 37 Europe Active Pharmaceutical Ingredients Market Share, By End-User, 2024 & 2033 (%)

Figure 38 Europe Active Pharmaceutical Ingredients Market Share, By Country, 2024 & 2033 (%)

Figure 39 Asia-Pacific Active Pharmaceutical Ingredients Market Value, 2022-2033 (US$ Billion)

Figure 40 Asia-Pacific Active Pharmaceutical Ingredients Market Share, By Type, 2024 & 2033 (%)

Figure 41 Asia-Pacific Active Pharmaceutical Ingredients Market Share, By Type of Synthesis, 2024 & 2033 (%)

Figure 42 Asia-Pacific Active Pharmaceutical Ingredients Market Share, By Application, 2024 & 2033 (%)

Figure 43 Asia-Pacific Active Pharmaceutical Ingredients Market Share, By End-User, 2024 & 2033 (%)

Figure 44 Asia-Pacific Active Pharmaceutical Ingredients Market Share, By Country, 2024 & 2033 (%)

Figure 45 South America Active Pharmaceutical Ingredients Market Value, 2022-2033 (US$ Billion)

Figure 46 South America Active Pharmaceutical Ingredients Market Share, By Type, 2024 & 2033 (%)

Figure 47 South America Active Pharmaceutical Ingredients Market Share, By Type of Synthesis, 2024 & 2033 (%)

Figure 48 South America Active Pharmaceutical Ingredients Market Share, By Application, 2024 & 2033 (%)

Figure 49 South America Active Pharmaceutical Ingredients Market Share, By End-User, 2024 & 2033 (%)

Figure 50 South America Active Pharmaceutical Ingredients Market Share, By Country, 2024 & 2033 (%)

Figure 51 Middle East and Africa Active Pharmaceutical Ingredients Market Value, 2022-2033 (US$ Billion)

Figure 52 Middle East and Africa Active Pharmaceutical Ingredients Market Share, By Type, 2024 & 2033 (%)

Figure 53 Middle East and Africa Active Pharmaceutical Ingredients Market Share, By Type of Synthesis, 2024 & 2033 (%)

Figure 54 Middle East and Africa Active Pharmaceutical Ingredients Market Share, By Application, 2024 & 2033 (%)

Figure 55 Middle East and Africa Active Pharmaceutical Ingredients Market Share, By End-User, 2024 & 2033 (%)

Figure 56 Pfizer Inc.: Financials

Figure 57 Teva Pharmaceuticals USA, Inc.: Financials

Figure 58 Merck KGaA: Financials

Figure 59 AbbVie Inc.: Financials

Figure 60 Aurobindo Pharma Limited: Financials

Figure 61 Dr. Reddy’s Laboratories Ltd.: Financials

Figure 62 Lupin: Financials

Figure 63 Sun Pharmaceutical Industries Ltd.: Financials

Figure 64 Divi's Laboratories Limited: Financials

Figure 65 Cipla: Financials

활성 의약품 원료 시장